Scott R Plotkin1, Simone L Ardern-Holmes, Fred G Barker, Jaishri O Blakeley, D Gareth Evans, Rosalie E Ferner, Tessa A Hadlock, Chris Halpin. 1. From the Neurology Department and Cancer Center (S.R.P.) and Neurosurgical Service (F.G.B.), Massachusetts General Hospital, Boston, MA; Department of Neurology and Neurosurgery (S.L.A.-H.), The Children's Hospital at Westmead, University of Sydney, Australia; Department of Neurology and Oncology (J.O.B.), John Hopkins Medical Institute, Baltimore, MD; University Department of Medical Genetics (D.G.E.), St Mary's Hospital, Manchester, UK; Department of Neurology (R.E.F.), Guy's and St. Thomas' NHS Foundation Trust and Institute of Psychiatry, King's College London, UK; Department of Otolaryngology (T.A.H.) and Audiology (C.H.), Massachusetts Eye and Ear Infirmary; and Harvard Medical School (T.A.H.), Boston, MA.
Abstract
OBJECTIVES: Vestibular schwannomas are the hallmark of neurofibromatosis 2 (NF2), occurring in >95% of patients. These tumors develop on the vestibulocochlear nerve and are associated with significant morbidity due to hearing loss, tinnitus, imbalance, facial weakness, and risk of early mortality from brainstem compression. Although hearing loss and facial weakness have been identified as important functional outcomes for patients with NF2, there is a lack of consensus regarding appropriate endpoints in clinical trials. METHODS: The functional outcomes group reviewed existing endpoints for hearing and facial function and developed consensus recommendations for response evaluation in NF2 clinical trials. RESULTS: For hearing endpoints, the functional group endorsed the use of maximum word recognition score as a primary endpoint, with the 95% critical difference as primary hearing outcomes. The group recommended use of the scaled measurement of improvement in lip excursion (SMILE) system for studies of facial function. CONCLUSIONS: These recommendations are intended to provide researchers with a common set of endpoints for use in clinical trials of patients with NF2. The use of common endpoints should improve the quality of clinical trials and foster comparison among studies for hearing loss and facial weakness.
OBJECTIVES:Vestibular schwannomas are the hallmark of neurofibromatosis 2 (NF2), occurring in >95% of patients. These tumors develop on the vestibulocochlear nerve and are associated with significant morbidity due to hearing loss, tinnitus, imbalance, facial weakness, and risk of early mortality from brainstem compression. Although hearing loss and facial weakness have been identified as important functional outcomes for patients with NF2, there is a lack of consensus regarding appropriate endpoints in clinical trials. METHODS: The functional outcomes group reviewed existing endpoints for hearing and facial function and developed consensus recommendations for response evaluation in NF2 clinical trials. RESULTS: For hearing endpoints, the functional group endorsed the use of maximum word recognition score as a primary endpoint, with the 95% critical difference as primary hearing outcomes. The group recommended use of the scaled measurement of improvement in lip excursion (SMILE) system for studies of facial function. CONCLUSIONS: These recommendations are intended to provide researchers with a common set of endpoints for use in clinical trials of patients with NF2. The use of common endpoints should improve the quality of clinical trials and foster comparison among studies for hearing loss and facial weakness.
Authors: Linda N Lee; Srinivas M Susarla; Marc H Hohman; Douglas K Henstrom; Mack L Cheney; Tessa A Hadlock Journal: Ann Plast Surg Date: 2013-03 Impact factor: 1.539
Authors: James R Tysome; Robert Macfarlane; Juliette Durie-Gair; Neil Donnelly; Richard Mannion; Richard Knight; Frances Harris; Zebunnisa H Vanat; Yu Chen Tam; Katherine Burton; Anke Hensiek; F Lucy Raymond; David A Moffat; Patrick R Axon Journal: Otol Neurotol Date: 2012-04 Impact factor: 2.311
Authors: Robert A Avery; James A Katowitz; Michael J Fisher; Gena Heidary; Eva Dombi; Roger J Packer; Brigitte C Widemann Journal: Ophthalmology Date: 2016-11-03 Impact factor: 12.079
Authors: Scott R Plotkin; Stephanie D Davis; Kent A Robertson; Srivandana Akshintala; Julian Allen; Michael J Fisher; Jaishri O Blakeley; Brigitte C Widemann; Rosalie E Ferner; Carole L Marcus Journal: Neurology Date: 2016-08-16 Impact factor: 9.910
Authors: Jaishri O Blakeley; Xiaobu Ye; Dan G Duda; Chris F Halpin; Amanda L Bergner; Alona Muzikansky; Vanessa L Merker; Elizabeth R Gerstner; Laura M Fayad; Shivani Ahlawat; Michael A Jacobs; Rakesh K Jain; Christopher Zalewski; Eva Dombi; Brigitte C Widemann; Scott R Plotkin Journal: J Clin Oncol Date: 2016-03-14 Impact factor: 44.544
Authors: Victoria Huang; Amanda L Bergner; Chris Halpin; Vanessa L Merker; Monica R Sheridan; Brigitte C Widemann; Jaishri O Blakeley; Scott R Plotkin Journal: Otol Neurotol Date: 2018-06 Impact factor: 2.311
Authors: Scott R Plotkin; Dan G Duda; Alona Muzikansky; Jeffrey Allen; Jaishri Blakeley; Tena Rosser; Jian L Campian; D Wade Clapp; Michael J Fisher; James Tonsgard; Nicole Ullrich; Coretta Thomas; Gary Cutter; Bruce Korf; Roger Packer; Matthias A Karajannis Journal: J Clin Oncol Date: 2019-10-18 Impact factor: 44.544
Authors: Steffen Rosahl; Christopher Bohr; Michael Lell; Klaus Hamm; Heinrich Iro Journal: GMS Curr Top Otorhinolaryngol Head Neck Surg Date: 2017-12-18
Authors: Heather L Thompson; Ann Blanton; Barbara Franklin; Vanessa L Merker; Kevin H Franck; D Bradley Welling Journal: Neurology Date: 2021-07-06 Impact factor: 11.800